Plant Name: Hordeum vulgare
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| HCAR2; HTR1B; HTR1D; TAAR1; HTR2A; HTR2C; HTR6; | |
| GAA; | |
| CA2; CA1; CA12; CA9; CA14; CA7; | |
| ESR2; | |
| ALOX5; PTGS2; | |
| MPO; IDO1; | |
| LMNA; RAB9A; NPC1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | IDO1 | Indoleamine 2,3-dioxygenase | P14902 | CHEMBL4685 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Small molecule receptor (family A GPCR) | HTR1B | Serotonin 1b (5-HT1b) receptor | P28222 | CHEMBL1898 |
| Small molecule receptor (family A GPCR) | HTR1D | Serotonin 1d (5-HT1d) receptor | P28221 | CHEMBL1983 |
| Small molecule receptor (family A GPCR) | TAAR1 | Trace amine-associated receptor 1 | Q96RJ0 | CHEMBL5857 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.038E-14 | 4.438E-10 | CA1, CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.798E-11 | 2.031E-07 | CA1, CA12, CA14, CA2, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 1.505E-10 | 3.641E-07 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 1.505E-10 | 3.641E-07 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.782E-10 | 8.235E-07 | CYP1A2, CYP2A6, CYP2D6, CYP3A4, IDO1, MPO, PTGS2 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 9.921E-10 | 1.543E-06 | HTR1B, HTR1D, HTR2A, HTR2C |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.319E-09 | 1.915E-06 | CA1, CA12, CA2, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.857E-08 | 5.876E-05 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.313E-07 | 3.990E-04 | CYP1A2, CYP2A6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 5.313E-07 | 3.990E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019369; arachidonic acid metabolic process | 9.126E-07 | 6.410E-04 | CYP1A2, CYP2A6, CYP2D6, PTGS2 |
| BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 1.882E-06 | 1.242E-03 | HTR2A, HTR2C |
| MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 1.882E-06 | 1.242E-03 | HTR2A, HTR2C |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.552E-06 | 1.502E-03 | ALOX5, CYP1A2, CYP2A6, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.016E-06 | 1.722E-03 | CA2, CA7, HCAR2, HTR2A, HTR2C, NPC1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.234E-06 | 2.192E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 5.640E-06 | 2.670E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.640E-06 | 2.670E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0016702; oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen | 6.198E-06 | 2.872E-03 | ALOX5, IDO1, PTGS2 |
| BP | Unclassified; | GO:0042310; vasoconstriction | 8.686E-06 | 3.628E-03 | HTR1B, HTR1D, HTR2A |
| BP | GO:0050896; response to stimulus | GO:0042221; response to chemical | 8.804E-06 | 3.628E-03 | CA2, CA9, CYP1A2, HTR1B, HTR1D, HTR2A, HTR2C, IDO1, LMNA, MPO, NPC1, PTGS2, TSHR |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.127E-05 | 4.231E-03 | CYP1A2, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.373E-05 | 4.981E-03 | CA2, CA7, HCAR2, NPC1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.416E-05 | 5.054E-03 | CYP2A6, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 1.877E-05 | 6.192E-03 | HTR2A, HTR2C |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 2.106E-05 | 6.744E-03 | CYP1A2, CYP2A6, CYP2D6, CYP3A4, NPC1 |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 2.532E-05 | 7.878E-03 | HTR1B, HTR1D, HTR2A, PTGS2 |
| MF | Unclassified; | GO:0004872; receptor activity | 2.618E-05 | 7.919E-03 | ESR2, HCAR2, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, NPC1, TAAR1, TSHR |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 2.813E-05 | 8.390E-03 | CA1, CA2 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 3.225E-05 | 9.154E-03 | HCAR2, HTR1B, HTR1D, HTR2A, HTR2C, HTR6, NPC1, TAAR1, TSHR |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.323E-05 | 9.190E-03 | CYP1A2, CYP2D6, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.525E-12 | 3.888E-11 | HTR6; CYP2D6; ALOX5; HTR1D; HTR1B; HTR2C; HTR2A; PTGS2 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.084E-14 | 2.083E-12 | CA12; CA1; CA2; CA7; CA9; CA14 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 6.350E-08 | 1.079E-06 | HTR6; HTR1D; HTR1B; HTR2C; HTR2A; TAAR1; TSHR |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.144E-06 | 2.734E-05 | CYP2A6; CYP2D6; CYP1A2; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.690E-06 | 2.744E-05 | CYP2A6; CYP2D6; CYP1A2; CYP3A4 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 6.266E-06 | 4.565E-05 | HCAR2; HTR6; HTR1D; HTR1B; TSHR |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.287E-06 | 3.644E-05 | CYP2A6; CYP1A2; CYP3A4; PTGS2 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.064E-05 | 5.136E-04 | CYP2A6; CYP1A2; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.020E-03 | 4.730E-03 | CYP2A6; GAA; ALOX5; CYP1A2; PTGS2; CYP3A4; IDO1 |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.789E-03 | 6.516E-03 | HTR6; HTR2C; HTR2A |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.326E-03 | 5.637E-03 | CYP1A2; IDO1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.066E-03 | 7.024E-03 | ALOX5; PTGS2 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.967E-04 | 3.553E-03 | CYP1A2; CYP3A4 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.584E-03 | 8.237E-03 | PTGS2; TSHR |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.751E-03 | 6.516E-03 | CYP2A6; CYP3A4 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.157E-03 | 8.946E-03 | ALOX5; PTGS2 |
| hsa04742 | Taste transduction_Homo sapiens_hsa04742 | 5.584E-03 | 1.424E-02 | HTR1D; HTR1B |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 7.702E-03 | 1.786E-02 | HTR2C; HTR2A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.769E-03 | 8.307E-03 | CYP1A2; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.118E-03 | 1.105E-02 | CA2; CYP3A4 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 6.255E-03 | 1.519E-02 | HTR2C; HTR2A |
| hsa04142 | Lysosome_Homo sapiens_hsa04142 | 1.191E-02 | 2.641E-02 | NPC1; GAA |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.751E-05 | 1.116E-04 | CYP2A6; CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | HTR6 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; HTR6 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; PTGS2 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; IDO1; PTGS2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; MPO; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | IDO1; HTR2C; HTR2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2C; HTR2A |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR2C; CYP3A4; HTR1B; HTR2A; HTR6; HTR6 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | HTR1D |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR2C; HTR2C; HCAR2; HTR1B; HTR1D |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR2C; HTR2C; HTR6 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR1D; HTR2A; CYP2D6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; HCAR2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A |
| NA: NA | Addiction | NA | HTR2A |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; HTR6; HTR6; HTR6 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; HCAR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2C; HTR2A |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HCAR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HCAR2; HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2C; HTR1B; HTR1D; HTR2A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1D |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C; HTR1B; HTR1D |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2C; HTR2A; HTR2A; HTR6 |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; PTGS2; PTGS2; PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MPO |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HTR2C; PTGS2; PTGS2; PTGS2; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Chronic schizophrenics | F20 | HTR1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HTR6 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; HTR1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| NA: NA | Primary insomnia | NA | HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | HTR1D |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |